GlassScriptPhysician profile
Stuart Arthur Allan
NPI 1649725151
$1,063.69
in general payments reported to CMS, 2019-2025
13 companies · $547 in 2025
The $547 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.50 · 2023: $86.51 · 2024: $402 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $408.78 | 2023-2025 | |
| Organogenesis INC. | $153.53 | 2024-2025 | Puraply Wound Matrix, Apligraf, Nushield |
| Paratek Pharmaceuticals, INC. | $136.57 | 2023-2025 | Nuzyra |
| Viiv Healthcare Company | $76.82 | 2024-2025 | Apretude, Rukobia, Dovato |
| Urgo Medical North America, LLC | $56.68 | 2024-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Smith+Nephew, INC. | $43.14 | 2024-2025 | Collagenase Santyl |
| Hartmann USA, INC. | $39.89 | 2024-2025 | Zetuvit Plus 10x10 P10 |
| Convatec INC. | $37.78 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $27.50 | 2021 | |
| Integra Lifesciences Corporation | $25.47 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Insmed, INC. | $21.33 | 2025 | Brinsupri, Arikayce |
| Mimedx Group, INC. | $20.88 | 2025 | |
| Reprise Biomedical, INC. | $15.32 | 2024 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Allan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.